As of 2024-12-13, the EV/EBITDA ratio of Tissue Regenix Group PLC (TRX.L) is 26.41. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TRX.L's latest enterprise value is 48.33 mil GBP. TRX.L's TTM EBITDA according to its financial statements is 1.83 mil GBP. Dividing these 2 quantities gives us the above TRX.L EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 21.3x | 18.2x |
| Forward P/E multiples | 24.9x - 27.9x | 27.2x |
| Fair Price | 27.97 - 59.65 | 47.46 |
| Upside | -51.8% - 2.8% | -18.2% |
| Date | EV/EBITDA |
| 2024-12-09 | 26.02 |
| 2024-12-06 | 26.41 |
| 2024-12-05 | 26.41 |
| 2024-12-04 | 26.41 |
| 2024-12-03 | 26.41 |
| 2024-12-02 | 26.41 |
| 2024-11-29 | 26.21 |
| 2024-11-28 | 26.21 |
| 2024-11-27 | 26.21 |
| 2024-11-26 | 26.02 |
| 2024-11-25 | 26.02 |
| 2024-11-22 | 26.02 |
| 2024-11-21 | 26.21 |
| 2024-11-20 | 26.80 |
| 2024-11-19 | 27.19 |
| 2024-11-18 | 27.58 |
| 2024-11-15 | 27.58 |
| 2024-11-14 | 27.77 |
| 2024-11-13 | 27.97 |
| 2024-11-12 | 27.97 |
| 2024-11-11 | 27.97 |
| 2024-11-08 | 27.65 |
| 2024-11-07 | 27.97 |
| 2024-11-06 | 27.58 |
| 2024-11-05 | 27.58 |
| 2024-11-04 | 27.38 |
| 2024-11-01 | 27.58 |
| 2024-10-31 | 26.99 |
| 2024-10-30 | 26.21 |
| 2024-10-29 | 25.05 |
| 2024-10-28 | 24.46 |
| 2024-10-25 | 24.85 |
| 2024-10-24 | 24.85 |
| 2024-10-23 | 24.85 |
| 2024-10-22 | 24.85 |
| 2024-10-21 | 24.85 |
| 2024-10-18 | 24.85 |
| 2024-10-17 | 24.85 |
| 2024-10-16 | 24.85 |
| 2024-10-15 | 24.85 |
| 2024-10-14 | 24.85 |
| 2024-10-11 | 24.85 |
| 2024-10-10 | 24.85 |
| 2024-10-09 | 24.85 |
| 2024-10-08 | 24.85 |
| 2024-10-07 | 24.85 |
| 2024-10-04 | 24.85 |
| 2024-10-03 | 24.85 |
| 2024-10-02 | 24.85 |
| 2024-10-01 | 24.85 |